Trelagliptin, as the world's first weekly oral DPP-4 inhibitor, has been on the market for different periods of time depending on the country and region. The drug was developed by Takeda Pharmaceuticals in Japan, and its approval time in different markets reflects its global promotion process.

1 Japanese market

(1) First approval: Approved for market launch in Japan in March 2015 under the brand name Zafatek.

(2) Indications: for blood sugar control of type 2 diabetes patients.

2 Other Asian markets

(1) South Korea: Approved in 2016.

(2) China: Currently, it has not been officially approved for listing domestically.

3 European and American markets

(1) United States: As of now, it has not received FDA approval.

(2) Europe: Not approved for market in the EU region.

4 Domestic Progress

(1) Clinical trial: Three phase clinical trials have been conducted in China.

(2) Listing status: Currently, it is still in an unlisted state and requires continuous monitoring of approval progress.